GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » DeferredTaxAndRevenue

Cleo Diagnostics (ASX:COV) DeferredTaxAndRevenue : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cleo Diagnostics's current deferred tax and revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cleo Diagnostics DeferredTaxAndRevenue Historical Data

The historical data trend for Cleo Diagnostics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics DeferredTaxAndRevenue Chart

Cleo Diagnostics Annual Data
Trend Jun23
DeferredTaxAndRevenue
-

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
DeferredTaxAndRevenue - - -

Cleo Diagnostics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » DeferredTaxAndRevenue
Comparable Companies
ASX:CVB ASX:ADR ASX:CSX ASX:CDX ASX:OSL ASX:AT1 ASX:CMP ASX:HMD ASX:RSH ASX:RNO ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Website
https://www.cleodx.com
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines